During the past decade, Center for Vaccine Development, Mali conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 2 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 1 clinical trials were completed. i.e. 11.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Center for Vaccine Development, Mali" #1 sponsor was "University of Maryland, Baltimore" with 5 trials, followed by "London School of Hygiene and Tropical Medicine" with 2 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials sponsored, "ANRS, Emerging Infectious Diseases" with 1 trials sponsored and "Center for Vaccine Development - Mali" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Center for Vaccine Development, Mali" #1 collaborator was "Bill and Melinda Gates Foundation" with 4 trials as a collaborator, "Center for Vaccine Development - Mali" with 3 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 3 trials as a collaborator, "Wellcome Trust" with 2 trials as a collaborator and "APHP" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Center for Vaccine Development, Mali" are "COVID-19" (2 trials), "Ebola Virus Disease" (2 trials), "Hemorrhagic Fever" (2 trials), "Meningitis" (2 trials) and "Clostridium Difficile Immunisation" (1 trials). Many other conditions were trialed in "Center for Vaccine Development, Mali" in a lesser frequency.

Most popular intervention types in "Center for Vaccine Development, Mali" are "Biological" (12 trials), "Other" (3 trials), "Device" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ad26.COV2.S" (1 trials), "Azithromycin to infants" (1 trials), "Azithromycin to pregnant women" (1 trials), "Booster-MVA-BN® Filo or saline placebo" (1 trials) and "Bubble CPAP" (1 trials). Other intervention names were less common.

The vast majority of trials in "Center for Vaccine Development, Mali" are 14 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Center for Vaccine Development, Mali". 2 are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Center for Vaccine Development, Mali, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Center for Vaccine Development, Mali, 3 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 2 trials that are defined as “Not Applicable".